Cerner wins the DoD EHR modernization contract

At long last, the winning vendors for the Defense Healthcare Management Systems Modernization (DHMSM) procurement effort have been named and they are Cerner, Leidos and Accenture. The group surprisingly beat out bids headed up by Allscripts and Epic.  

The three partnered in submitting a bid in which defense computing contractor Leidos will serve as the prime contractor and Accenture as the configuration specialist.

Originally valued at $11 billion, the contract is now worth $4.3 billion and could extend as long as 10 years. The winning companies now will be responsible for upgrading the disparate electronic medical records of 9.5 million active-duty service members and their families. The overhaul will affect 56 hospitals and hundreds of medical and dental clinics in 16 countries.

The project comes with a certain amount of controversy. There have been lots of questions in recent years about why the Defense Department couldn’t make its open-source VistA system work. And, the Government Accountability Office has put this modernization project on its list of high-risk government initiatives, noting that federal agencies have wasted billions on failed IT investments over the years.

 

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.